Exhibit 1282 ยท Statute
Continuing Appropriations and Ukraine Supplemental Appropriations Act, 2023, Pub. L. 117-180, Division F, Title I (Prescription Drug User Fee Amendments of 2022)
Congress finds that the fees authorized by the amendments made by this title will be dedicated toward expediting the drug development process and the process for the review of human drug applications, including postmarket drug safety activities
Title I of the FDA User Fee Reauthorization Act of 2022, enacted inside a continuing appropriations act, is the Prescription Drug User Fee Amendments of 2022 (PDUFA VII). Approved 30 September 2022.
- Source
- United States Congress
- Date
- 30 September 2022
- Quoted from
- Sec. 1001(b)
- Grade
- Primary record
- Document
- https://www.govinfo.gov/content/pkg/PLAW-117publ180/html/PLAW-117publ180.htm
- Accessed
- 2026-11-10
- Cited by
- Findings citing this exhibit